WS Value & Dossier GmbH
Your specialists for market access and reimbursement
How the German AMNOG process works
Value & Dossier GmbH advises pharmaceutical companies and biotechnology companies throughout the AMNOG process and on all matters relating to market access and reimbursement. Based on our long-standing expertise, we advise you on the development of the best strategy, the preparation of your benefit dossier for the G-BA assessment and the price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).
Your success is what drives us. We will make sure that your new product will be reimbursed in the best possible way.
Our Services
“We offer individual and company-specific solutions focussing on the value of the product while implementing it accordingly in the required benefit dossiers.”
Recent Articles
EU-HTA: Open call for Joint Scientific Consultations
EUnetHTA21 offers early dialogue Joint Scientific Consultations (JSC) in parallel to the EMA scientific advice for medicinal products
Challenges and Chances of the EU-HTA
The first medicinal products used to treat oncologic diseases and ATMPs will be assessed within the framework of